RMD
ResMedNYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-05-08
As of May 8, 2026, RMD has a composite score of 24.0 and a signal label of "mild favorable." The score reflects medium confidence at 73.7 and is influenced by various factors, including a macro score of 31.5 and a management score of 66.3. The analysis is provisional, indicating that the current assessments may be subject to change.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)0.18
- Bonus0.00
Why this rank
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $2.89 → $2.90 (+0.2% / 30d). 9 raised, 4 cut, 13 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 58% of analysts rate Buy.
3 PT revisions / 30d. Avg target 18.0% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
5 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Invest in innovation and digital healthgrowthwatchprovisional
7/31: “As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities...”
Why this status
Stated in 2 of last 2 quarters. Revenue grew from $981.7M in 2025-Q4 to $1.42B in 2026-Q2, indicating strong demand for digital health and innovation initiatives. The trajectory is delivering on the stated priority.
- 2.Maintain gross margin guidancecostmixed65% progress
4/30: “Resmed reported results for its third quarter fiscal year 2026 today and is reiterating its outlook for fiscal year 2026, including gross margin in the range of 62-63%”
Why this status
Newly stated in 2026-Q2. The company reiterated its gross margin guidance of 62-63% for fiscal year 2026. However, specific gross margin figures for the quarter were not disclosed, making it difficult to assess delivery against this priority.
- 3.CFO transition managementtalentwatchprovisional
4/30: “On April 30, 2026, ResMed Inc. announced that Brett Sandercock, Chief Financial Officer, will retire from his role.”
Why this status
Newly stated in 2026-Q2. The announcement of the CFO's retirement indicates a focus on managing the transition. The impact on financial operations remains to be seen, as no immediate financial effects were disclosed.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 23%; 252d 22%.
Drawdown — Max 1y −30%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.67 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 63/100, drawdown 40/100, beta 67/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 2 guided quarters · 2.0% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Invest in innovation and digital health
GrowthNew since 2026-05-04Focus on scaling digital health capabilities and innovation in sleep and respiratory care devices.
WatchStated in 2 of last 2 quarters. Revenue grew from $981.7M in 2025-Q4 to $1.42B in 2026-Q2, indicating strong demand for digital health and innovation initiatives. The trajectory is delivering on the stated priority.
Revenue grew from $981.7M in 2025-Q4 to $1.42B in 2026-Q2No scoreCEO/CFO:“As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities...”Multiple sourcesSource dated 2025-07-31Stated 2 of last 8 quartersFirst seen 2026-05-04provisionalShow history (2)
- 2026-Q2Multiple sources
“These results reflect strong ongoing demand for our market-leading sleep and respiratory care devices...”
- 2025-Q4Multiple sources
“As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities...”
- #2
Maintain gross margin guidance
CostNew since 2026-05-04Ensure gross margin remains within the guided range of 62-63%.
MixedNewly stated in 2026-Q2. The company reiterated its gross margin guidance of 62-63% for fiscal year 2026. However, specific gross margin figures for the quarter were not disclosed, making it difficult to assess delivery against this priority.
65%CEO/CFO:“Resmed reported results for its third quarter fiscal year 2026 today and is reiterating its outlook for fiscal year 2026, including gross margin in the range of 62-63%”Multiple sourcesSource dated 2026-04-30Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q2Multiple sources
“Resmed reported results for its third quarter fiscal year 2026 today and is reiterating its outlook for fiscal year 2026, including gross margin in the range of 62-63%”
- #3
CFO transition management
TalentNew since 2026-05-04Manage the transition of the Chief Financial Officer role effectively.
WatchNewly stated in 2026-Q2. The announcement of the CFO's retirement indicates a focus on managing the transition. The impact on financial operations remains to be seen, as no immediate financial effects were disclosed.
No scoreCEO/CFO:“On April 30, 2026, ResMed Inc. announced that Brett Sandercock, Chief Financial Officer, will retire from his role.”Multiple sourcesSource dated 2026-04-30Stated 1 of last 8 quartersFirst seen 2026-05-04provisionalShow history (1)
- 2026-Q2Multiple sources
“On April 30, 2026, ResMed Inc. announced that Brett Sandercock, Chief Financial Officer, will retire from his role.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
RMD ResMed | +24 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-30)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-30)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-308d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. Mr. Sandercock will continue to serve as Chief Financial Officer un…
executive changeneutralscore 66 - 2026-04-308d agoItem 2.02
and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 55 - 2026-04-308d agoItem 8.01
Other Events. On April 30, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the ex…
capital allocationneutralscore 43 - 2026-01-293mo agoItem 2.02
and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 7 - 2026-01-293mo agoItem 8.01
Other Events. On January 29, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. The dividend will have a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the e…
capital allocationneutralscore 5
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.